Yes, Patients Must Avoid Pregnancy for 6 Months After Completing Tepezza or Lumvoa
Women of reproductive potential must use effective contraception for 6 months following the last dose of both Tepezza (teprotumumab) and Lumvoa (veligrotug), as both drugs inhibit IGF-1R which is critical for fetal skeletal development and can cause severe fetal harm.
Rationale Based on Mechanism of Action
Both medications are monoclonal antibodies targeting the insulin-like growth factor-1 receptor (IGF-1R), which plays an essential role in fetal skeletal development. The FDA drug label for Tepezza explicitly states that appropriate contraception is strictly recommended before initiation, during treatment, and for 6 months following completion of therapy 1. This recommendation is based on:
- Drug half-life: Teprotumumab has a half-life of approximately 20 days 2
- Fetal risk: Animal studies showed multiple external and skeletal abnormalities in exposed fetuses, including misshapen cranium, closely set eyes, micrognathia, and ossification abnormalities of skull bones, sternebrae, carpals, tarsals and teeth 1
- Increased fetal loss: Teprotumumab exposure led to higher abortion rates in animal studies 1
Clinical Guidelines Alignment
The 2022 Journal of Clinical Endocrinology & Metabolism guidelines emphasize that IGF-1 is critical in fetal skeletal development; therefore, appropriate contraception is strictly recommended before initiation, during treatment, and, given the long half-life of the drug (20 days), for 6 months following completion of therapy in women of reproductive age 2. Pregnancy and lactation are absolute contraindications to treatment 2.
Practical Implementation
Before starting treatment:
- Obtain baseline pregnancy test in all premenopausal women 2
- Counsel on contraception requirements extending 6 months post-treatment
- Document patient understanding and contraceptive plan
During treatment:
- Pregnancy testing before each infusion 2
- If pregnancy occurs, immediately discontinue therapy and advise patient of potential fetal risks 1
Post-treatment:
- Continue effective contraception for full 6 months after last infusion
- This allows approximately 5 half-lives for complete drug elimination
Important Caveats
While the FDA label for Tepezza provides explicit guidance 1, Lumvoa (veligrotug) is newer with similar mechanism of action and should follow the same precautions given its IGF-1R antagonism 3. The 6-month waiting period is conservative but necessary given the severity of potential fetal abnormalities and the uncertainty about tissue bioavailability beyond serum half-life calculations.
The recommendation applies equally to both medications due to their shared mechanism targeting IGF-1R, regardless of whether specific pregnancy data exists for Lumvoa, as the biological rationale for fetal harm is identical.